anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine.SUBSTANCE: waste skin is incised on the periphery of the wound. The incised skin is prepared from the residual subcutaneous fat and milled to fragments having an area of 1-2 mm. A dermal matrix made of dead donor's tissue is simulated after the wound shape. The dermal matrix (DM) is perforated to create traumatic discharge outflow tracts and laid on a wound bed so that to form a diastasis between perforation edges. Patient's waste skin fragments are introduced into the perforations in a staggered order. The wound is closed with a sterile gauze dressing. The other invention is allogenic mesenchymal multipotent stromal cell (MMSC) transplantation onto the wound bed in the form of the suspension by means of injections at a depth of 0.1-0.3 mm at a rate of 10 injections per 1 cm. A volume of each injection makes 0.05-0.1 ml. The dermal matrix made of dead donor's tissue is simulated after the wound shape. That is perforated to form the traumatic discharge outflow tracts and laid on the wound bed. The wound is closed with the sterile gauze dressing. The effect is ensured by using the DM as an optimum biocompatible cell carrier and creating a required micromedium in the wound, stimulating the regeneration processes ensured by a combination with the homogenised autologous skin or allogenic MMSC injections into the wound.EFFECT: inventions provide optimising skin and soft tissue wound healing ensured by stimulating the regeneration processes by means of stromal cells, including allo- and auto-MMSC and resident stem cells.5 cl, 2 ex
Inflammation is a multifaceted biological process in which the conversion of arachidonic acid to eicosanoids, including prostaglandins and leukotrienes (LTs), plays a crucial role. 5-Lipoxygenase (5-LOX) is a key enzyme in cellular LT biosynthesis, and it is supported by the accessory protein 5-lipoxygenase-activating protein (FLAP). Pharmacological interventions to modulate LTs aim at either decreasing their biosynthesis or at mitigating their biological effects. Therefore, inhibiting 5-LOX or FLAP represents a useful strategy to reduce inflammation. Herein we present the identification and pharmacological evaluation of novel inhibitors targeting 5-LOX or FLAP. By means of a ligand-based virtual screening approach, we selected 38 compounds for in vitro assays. Among them, ALR-38 exhibits direct 5-LOX inhibition, while ALR-6 and ALR-27 showed potential as FLAP inhibitors. These latter not only reduced LT production but also promoted the generation of specialized pro-resolving mediators in specific human macrophage phenotypes. Interestingly, the identified compounds turned out to be selective for their respective targets, as none of them displayed activity towards microsomal prostaglandin E2 synthase-1 and soluble epoxide hydrolase, which are other proteins involved in eicosanoid biosynthesis. Thus, these compounds are endowed with potential therapeutic utility in mitigating inflammatory responses and might offer a venue for tackling inflammation-based disorders.
If randomized to laser therapy at time of cataract surgery, laser therapy will be performed one month after cataract surgery. If macular edema does not respond an additional laser therapy will be performed. If macular edema persists after 2 lasers, then IVTA will be administered as per standard of care.
Galectin-9 is a physiologically active substance having an activity as lectin, whose expression is observed in various cells. Since there is found a correlation between the expression amount of galectin-9 and the metastasis capability of a tumor, it is predicted that galectin-9 is involved in various physiological phenomena. A substance capable of controlling the production/release of galectin-9 is expected to have activities such as an activity of inducing anti-tumor effect and anti-inflammatory effect and it is demanded to elucidate this substance. It is now found that a factor capable of inducing the production/release of galectin-9 (' a galectin-9 induction factor') occurs in a certain tumor cell membrane solubilized fraction. The factor can be given as a concanavalin A adsorbed fraction or a concentrated activity-retaining fraction by utilizing a Resource QTM ion exchange column, hydroxyapatite column or the like. It becomes possible to develop a measurement reagent, a pharmaceutical, an assay or the like by utilizing the galectin-9 induction activity of the factor.
INTRODUCTION: Atrioventricular block may be idiopathic or a secondary manifestation of an underlying systemic disease. Cardiac sarcoidosis is a significant underlying cause of high-grade atrioventricular block, posing diagnostic challenges and significant clinical implications. This study aimed to assess the prevalence and clinical characteristics of cardiac sarcoidosis among younger patients presenting with unexplained high-grade atrioventricular block.
METHODS: We evaluated patients aged between 18 and 65 years presenting with unexplained high-grade atrioventricular block, who were systematically referred for cardiac magnetic resonance imaging, positron emission tomography-computed tomography, or both, prior to pacemaker implantation. Subjects with suspected cardiac sarcoidosis based on imaging findings were further referred for tissue biopsy. Cardiac sarcoidosis diagnosis was confirmed based on biopsy results.
RESULTS: Overall, 30 patients with high-grade atrioventricular block were included in the analysis. The median age was 56.5 years (interquartile range 53-61.75, years). In 37%, cardiac magnetic resonance imaging, positron emission tomography-computed tomography, or both, were suggestive of cardiac sarcoidosis, and in 33% cardiac sarcoidosis was confirmed by tissue biopsy. Compared with idiopathic high-grade atrioventricular block patients, all cardiac sarcoidosis patients were males (100% vs 60%, P = .029), were more likely to present with heart failure symptoms (50% vs 10%, P = .047), had thicker inter-ventricular septum on echocardiography (12.2 ± 2.7 mm vs 9.45 ± 1.6 mm, P = .002), and were more likely to present with right ventricular dysfunction (33% vs 10%, P = .047).
CONCLUSIONS: Cardiac sarcoidosis was confirmed in one-third of patients ≤ 65 years, who presented with unexplained high-grade atrioventricular block. Cardiac sarcoidosis should be highly suspected in such patients, particularly in males who present with heart failure symptoms or exhibit thicker inter-ventricular septum and right ventricular dysfunction on echocardiography.
The placebo will be created by diluting 1ml of sodium chloride 0.9% in 100ml of sodium chloride in a sterile manner prior to application. The container will be identically labelled as the verum. The placebo will be applied by the same team members named above via the same route (intravenously), with the same speed and the same timing. All other parts of the procedure are identical as to the procedure described above.
BACKGROUND: Infections are responsible for ∼13% of cancer cases worldwide, with human papillomavirus (HPV) and hepatitis B (HBV) among the infections associated with cancer for which vaccines are available. The aim of this study was to estimate the indirect cost of premature mortality related to cancers caused by HPV and HBV in Middle East and North Africa (MENA) countries.
METHODS: The number of deaths and years of life lost (YLL) in 2019 from four HPV-related cancers: cervical cancer, oral cavity cancer, laryngeal cancer, and oropharynx cancer, as well as HBV-related liver cancer were sourced from the Institute for Health Metrics Evaluation (IHME) Global Burden of Disease database. HPV-attributable fractions were applied to deaths and YLL. The human capital approach was used to measure productivity loss, through value of YLL (VYLL), and estimated using gross domestic product per capita (World Bank; in USD). Seventeen countries in the MENA region were included. Four countries in the region were not included due to data availability.
RESULTS: In 2019, there were 11,645 potentially vaccine-preventable cancer-related deaths across the MENA region. This resulted in an indirect cost of $1,688,821,605, with 76.1% of this accrued in the Middle East ($1,284,923,633). The number of deaths in the Middle East (5,986) were similar to Northern Africa (5,659) but YLL were higher in Northern Africa (179,425) compared to the Middle East (169,207). The highest indirect cost per death occurred in Qatar ($1,378,991), compared to $14,962 in Sudan. Oral cavity cancer had the highest VYLL per death ($186,084).
CONCLUSIONS: There is a high burden of premature mortality and indirect costs of potentially vaccine-preventable cancer-related deaths in the MENA region. Improved vaccination program implementation, increased vaccine coverage of HPV and HBV vaccinations, and continued prioritization of public health measures, such as screening, could effectively reduce premature mortality and associated costs.
Intervention group participants will adopt a low-fat, plant-based diet for 12 weeks. Participants will be provided with a commercially available supplement containing 100 micrograms of vitamin B12 and asked to take it daily during the study. Alcoholic beverages will be limited to 1 per day. Participants will be asked to keep their physical activity level constant.
Process for valuation of particularly anti-rheumatic effects of curative mud without redundant water is characterised by that the mud, prepared of young mud by maturing process containing mostly sulphur compounds, iron, manganese and desulphicating bacteria, is submitted to progressive multistep extraction of effective components. The extraction in particular steps is realised with continual mixing, mostly during 24 hours with ratio of curative mud to extracting substance at least 1 : 1. In the first step the curative mud is extracted by diluents mixable with water, the suspension is filtered and the filtrate is in the reduced pressure and under the temperature most 50 °C thickened with producing the extract No. 1. The extract No. 1 is subsequently, in the second step, submitted to the extraction under the same conditions as in the first step by diluents partially mixable with water, the suspension is filtered, filtrate is thickened, the obtained extract No. 2 is dried, flattened and in the third step under the same conditions as in the first and second steps is extracted by diluent non-mixable with water, the filtrate is thickened with producing the extract No. 3. The extract No. 3 is submitted to other extraction by non-polar diluent and after the suspension filtration and filtrate thickening the extract No. 4 is obtained. The biological effect of the extracts from the particular steps is after the dissolving in the organic diluent or its mixture with water valued after the application to the biological model in the presence of suitable substrate.
The invention discloses a traditional Chinese medicine preparation for treating spleen-stomach deficiency type chronic pancreatitis. In clinic, most of chronic pancreatitis patients suffer from the disease for a long time with clinical features of weakness of the spleen and the stomach. The disease reoccurs and trends to be complex due to improper diet or emotional disorder, and usually has pathogenesis qi-stagnation inducted blood-stasis to form asthenia in origin and asthenia in superficiality; the most basic pathological change for weakness of the spleen and the stomach is structural and functional abnormity of a digestive system. Treatment for spleen-stomach deficiency type chronic pancreatitis based on syndrome differentiation must lay emphasis on regulating Qi and strengthening spleen. The traditional Chinese medicine preparation is decocted with water into decoction in a preparation chamber of the hospital by selecting the following traditional Chinese medicines with the effects of regulating qi and strengthening spleen, namely dutchmanspipe root, butterfly passiflora, scarlet kadsura root, pedunculate acronychia wood, trifoliate orange, root of woolly lespedeza, caragana rosea, sow thisle, dwarf cowlily seed and beautiful galangal fruit. According to the clinical test, the traditional Chinese medicine preparation is remarkable in curative effect, has the total effective rate of 95%, and is low in treatment cost and small in side effect.
A controlled release pharmaceutical composition of a selective serotonin reuptake inhibitor. The composition essentially comprises of a core comprising the active ingredient, one or more controlled release polymer(s) and one or more pharmaceutically acceptable excipients. The composition optionally will have a coating comprising one or more controlled release polymers. The composition is prepared by mixing the active ingredient with one or more controlled release polymers and one or more pharmaceutically acceptable excipients. Thereafter the mixture is granulated, dried, lubricated and compressed into tablets. The composition is used in the manufacture of a medicament, for treating and/or preventing the disorders. The active is released between about 2-8 hours with about 10-25% of active is released in vitro in 2 hours in 0.1N HCl, 750 ml dissolution medium using USP Dissolution tester, paddle method at 150 rpm. About 20-55%, 50-75% and 70-95% of active is released in vitro in 4,6 and 8 hours respectively in pH 7.5 Tris buffer, 1000 ml dissolution medium using USP Dissolution tester, paddle method at 150 rpm.
Patients receive decitabine IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 4-6 weeks for a minimum of 4 courses in the absence of disease progression or unacceptable toxicity.
Pharmacodynamic studies have shown that acamprosate calcium reduces alcohol intake in alcohol-dependent animals in a dose-dependent manner and that this effect appears to be specific to alcohol and the mechanisms of alcohol dependence.

Acamprosate calcium has negligible observable central nervous system (CNS) activity in animals outside of its effects on alcohol dependence, exhibiting no anticonvulsant, antidepressant, or anxiolytic activity.

The administration of acamprosate calcium is not associated with the development of tolerance or dependence in animal studies. Campral did not produce any evidence of withdrawal symptoms in patients in clinical trials at therapeutic doses. Post marketing data, collected retrospectively outside the U.S. have provided no evidence of Campral abuse or dependence.

Campral is not known to cause alcohol aversion and does not cause a disulfiram-like reaction as a result of ethanol ingestion.
This group will be follow up in Primary Care at 1, 3 and 6 month. At each visit patients receive advice on CPAP treatment, management of adverse effects associated with CPAP, making anthropometric and blood pressure measurements and also were asked to complete questionnaires.
It will consist of 18 sessions, 3 times a week, for 6 consecutive weeks; on the one hand, 12 face-to-face sessions of approximately 90 minutes duration, in which the Physical Therapy treatment will be carried out based on training of specific tasks directed to objectives and training of gait with a treadmill; In addition, a therapeutic education program will be carried out, with 6 telehealth sessions lasting approximately 60 minutes, which will include action observation activities. The face-to-face sessions will be held at the Physical Therapy Teaching Unit at University of Alcalá, and the telehealth sessions of the Therapeutic Education program will be carried out by remote assistance through a digital platform. All will be carried out by specialist Physical Therapists, members of the research team.
The present invention relates to a hyaluronate mesh film and a method for manufacturing the same. Particularly, the hyaluronate mesh film retains its shape as it is even in a hydrated state, and thus can be used for a cosmetic mask pack, patch for a medical instrument, wound covering material, or the like. The hyaluronate mesh film according to the present invention is characterized in that hyaluronate is infiltrated into the openings of a mesh sheet. Unlike the conventional product, the hyaluronate mesh film according to the present invention is not torn when being detached from a base film, and can be detached while maintaining its shape before drying. In addition, since the thickness of the film can be controlled freely, the hyaluronate mesh film can be manufactured with ease. In addition, the hyaluronate mesh film retains its shape as it is even in a hydrated state, and thus can be applied to various uses, such as cosmetics, medicines, packs for medical instruments, patches, artificial skin, or the like.
The I-ABM will include four progressively difficult levels of training blocks, each containing 72 trials. Participants will be required to tap or swipe the probe in the correct direction during the first and second levels of training. The inhibitory control components will be included in the third and fourth levels, where participants should not respond to the probe under certain conditions. Each training will take 10-15 minutes, and participants will complete the sessions three times a week for three weeks.
The entire mouth will be treated (supra-/subgingival) in a single session. If the patient has been identified to receive the control treatment, all teeth present will receive the application of disclosing agent, full-mouth supragingival and intra-sulcular biofilm removal with Airflow at sites with PD up to 4 mm, full mouth supra gingival calculus removal with USD, and subgingival biofilm removal with USD at sites with PD\> 4 mm, including the experimental sites, as required.
Substance use disorder (SUD) and human immunodeficiency virus (HIV) are synergistic epidemics (syndemics) disproportionately affecting Black Americans. Structural racism related to inadequate access to healthcare, stigma, and criminalization, especially among those with intersectional identities related to gender and sexual minorities, further exacerbate disparities in HIV and SUD outcomes.

SUD is often unrecognized and untreated among people living with HIV (PLWH). Only about half of HIV care sites routinely screen and refer to SUD treatment. In preliminary work, the study investigators found that nearly half of patients assessed in an HIV clinic waiting room met the criteria for an SUD, but 65% had not been diagnosed with SUD. A promising strategy to address structural barriers to SUD screening for PLWH is use of electronic patient portals. Patient portals are secure websites that give patients access to health information and allow for secure messaging with providers. They are associated with improved health outcomes and patient engagement. Notably, while most SUD screening currently occurs during clinic visits, portals can be utilized for SUD screening to reach patients who miss clinic visits, which is more common among people with HIV and SUD. The study team's preliminary work has demonstrated the potential of the portal for use in a population health approach to behavioral health screening.

This study will implement and evaluate multi-level interventions to decrease barriers to SUD screening (clinic-based, in-person) and treatment (referral-focused), a program the study investigators call Achieving Equity in Patient Outcome Reporting for Timely Assessments of Life With HIV and Substance Use (ePORTAL HIV-S). ePORTAL HIV-S is conducting a randomized control trial to assess the effectiveness of population health vs. usual (clinic-visit) SUD screening among PLWH in an HIV clinic. The randomized control trial will be conducted at the Chicago Department of Public Health-funded South Side Health Home (S2H2), the main provider of HIV prevention and care services for Chicago's South Side. The ePORTAL HIV S study will also include a referral to a clinic-based treatment.
RATIONALE: Ileal perforation caused by the insertion of a drainage tube is a rare complication. Hence, the utilization of surgical drains in abdominal surgery remains controversial. At present, there is a trend to reduce the utilization of drains in abdominal surgery, although certain situations may necessitate their application.
PATIENT CONCERNS: A 25-year-old Chinese woman presented with a history of right lower abdominal pain persisting for 10 days. Imaging examinations, including abdominal computed tomography and ultrasound, identified low-density lesions measuring 10 × 8 × 8cm3 in the right lower abdomen, which are consistent with perforated appendicitis complicated by a peri-appendiceal abscess. A laparoscopic appendectomy was carried out. On the 5th postoperative day, the drainage fluid changed to a grass-green color (80mL). Imaging with retrograde contrast through the drainage tube revealed that the 26 Fr silicon rubber drainage tube tip was positioned 50cm away from the ileocecal junction within the ileum. Both the ileal and ileocecal regions appeared well-developed.
INTERVENTION AND OUTCOMES: Oral intake was suspended, and the patient received antacids, somatostatin, antibiotics, and total parenteral nutrition. On the 19th postoperative day, a follow-up imaging procedure using retrograde contrast through the drainage tube indicated that the tube tip was sealed. The treatment concluded on day 33 postoperatively, and the patient was discharged.
DISCUSSION AND CONCLUSION: Ileal perforation due to an abdominal drainage tube following laparoscopic appendectomy constitutes a rare but serious complication. However, due to the adhesion and inflammatory changes around the abscess, laparoscopic dissection becomes a challenging and risky process, and the surgical skills and experiences are particularly important. Removing the abdominal drainage tube promptly based on the characteristics of the drainage fluid is recommended. The findings provide valuable insights for surgeons navigating similar challenges.
BACKGROUND: Pre-diabetes mellitus (DM) is associated with proteinuria, a risk factor for chronic kidney disease. While people with human immunodeficiency virus (HIV; PWH) have a higher risk of proteinuria than people without HIV (PWOH), it is unknown whether incident proteinuria differs by HIV serostatus among prediabetic persons.
METHODS: The urine protein-to-creatinine ratio was measured at semiannual visits among men in the Multicenter AIDS Cohort Study since April 2006. Men with pre-DM on or after April 2006 and no prevalent proteinuria or use of antidiabetic medications were included. Pre-DM was defined as a fasting glucose level of 100-125 mg/dL confirmed within a year by a repeated fasting glucose or hemoglobin A1c measurement of 5.7%-6.4%. Incident proteinuria was defined as a urine protein-to-creatinine ratio (UPCR) >200 mg/g, confirmed within a year. We used Poisson regression models to determine whether incident proteinuria in participants with pre-DM differed by HIV serostatus and, among PWH, whether HIV-specific factors were related to incident proteinuria.
RESULTS: Between 2006 and 2019, among 1276 men with pre-DM, proteinuria developed in 128 of 613 PWH (21%) and 50 of 663 PWOH (8%) over a median 10-year follow-up. After multivariable adjustment, the incidence of proteinuria in PWH with pre-DM was 3.3 times (95% confidence interval, 2.3-4.8 times) greater than in PWOH (P < .01). Among PWH, current CD4 cell count <50/µL (P < .01) and current use of protease inhibitors (P = .03) were associated with incident proteinuria, while lamivudine and integrase inhibitor use were associated with a lower risk.
CONCLUSIONS: Among men with pre-DM, the risk of incident proteinuria was 3 times higher in PWH. Strategies to preserve renal function are needed in this population.